2011279450 30 Jan 2015

What is claimed is:

1. A pharmaceutical formulation comprising:

(i) about 0.1 to 100 mg/ml of a human antibody that specifically binds to human nerve growth factor (hNGF), wherein the antibody comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pairs selected from the group consisting of: (a) SEQ ID NOs: 20/22; and (b) SEQ ID NOs 4/12;

(ii) about 0.01 to 1.0% of a polysorbate 20;

(iii) about 1 to 20% of sucrose; and

(iv) about 1 mM to about 50 mM acetate,

wherein 90% or more of the antibody is detected by size-exclusion-high-performance liquid chromatography (SE-HPLC) when stored at 5°C for six months.

2. The pharmaceutical formulation of claim 1, further comprising at least one amino acid selected from the group consisting of histidine or arginine.

3. The pharmaceutical formulation of claim 1 comprising: (i) about 0.2 to 75 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.02 to 0.5% polysorbate 20; and (iii) about 5 to 10% sucrose.

4. The pharmaceutical formulation of claim 3, comprising: (i) about 0.6-60 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.5% polysorbate 20; and (iii) about 8% sucrose.

5. The pharmaceutical formulation of claim 1, further comprising:

a glass container selected from the group consisting of a glass vial, a glass syringe, a plastic vial, and a plastic syringe.

6. The formulation of claim 5, wherein the container is a glass vial comprising a silicon dioxide coated glass.

7. The formulation of claim 6, wherein the glass vial is filled with the formulation leaving headspace filled with an inert gas.

8. The formulation of claim 7, wherein the inert gas is selected from the group consisting of argon and nitrogen.

30 Jan 2015 2011279450

9. The pharmaceutical formulation of claim 1, further comprising:

a container selected from the group consisting of an autoinjector, and a microinfusor.

10. The pharmaceutical formulation of claim 5, wherein the glass container is the syringe and the syringe is a syringe comprising a fluorocarbon-coated plunger.

11. The pharmaceutical formulation of claim 10, wherein the syringe is a low tungsten syringe.

12. The pharmaceutical formulation of claim 11, wherein the syringe comprises a fluorocarbon-coated plunger.

13. A pharmaceutical formulation comprising:

(i) about 0.1-100 mg/mL of a human antibody that specifically binds to human nerve growth factor (hNGF);

(ii) about 0.05% polysorbate 20;

(iii) about 8% sucrose; and

(iv) about 10 mM acetate,

wherein said antibody comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pairs selected from the group consisting of: (a) SEQ ID NOs:20/22; and (b) SEQ ID NOs 4/12,

wherein 90% or more of the antibody is detected by size-exclusion-high-performance liquid chromatography (SE-HPLC) when stored at 5°C for six months.

14. The pharmaceutical formulation of claim 13, wherein the pH of the formulation ranges from about 4.5 to 5.6.

15. The pharmaceutical formulation of claim 14, wherein the pH of the formulation is 5.0.

16. The pharmaceutical formulation of claim 13, further comprising:

a glass container selected from the group consisting of a glass vial, a glass syringe, a plastic vial, and a plastic syringe.

17. The formulation of claim 16, wherein the container is a glass vial comprising a silicon dioxide coated glass.

18. The formulation of claim 17, wherein the glass vial is filled with the formulation leaving headspace filled with an inert gas.

2011279450 30 Jan 2015

19. The formulation of claim 18, wherein the inert gas is selected from the group consisting of argon and nitrogen.

20. The pharmaceutical formulation of claim 13, further comprising:
a container selected from the group consisting of an autoinjector, and a microinfusor.

21. The pharmaceutical formulation of claim 16, wherein the glass container is the syringe and the syringe is a syringe comprising a fluorocarbon-coated plunger.

22. The pharmaceutical formulation of claim 21, wherein the syringe is a low tungsten syringe.

23. The pharmaceutical formulation of claim 22, wherein the syringe comprises a fluorocarbon-coated plunger.

24. The pharmaceutical formulation of claim 1 or 13, wherein 95% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.

25. The pharmaceutical formulation of claim 1 or 13, wherein 96% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.

26. The pharmaceutical formulation of claim 1 or 13, wherein 97% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.

27. The pharmaceutical formulation of claim 1 or 13 as herein described substantially as herein described with reference to any of the Examples and/or Figures.

What is claimed is:

1. A pharmaceutical formulation comprising:

(i) about 0.1 to 100 mg/ml of a human antibody that specifically binds to human nerve growth factor (hNGF), wherein the antibody comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pairs selected from the group consisting of: (a) SEQ ID NOs: 20/22; and (b) SEQ ID NOs 4/12;

(ii) about 0.01 to 1.0% of a polysorbate 20;

(iii) about 1 to 20% of sucrose; and

(iv) about 1 mM to about 50 mM acetate,

wherein 90% or more of the antibody is detected by size-exclusion-high-performance liquid chromatography (SE-HPLC) when stored at 5°C for six months.

2. The pharmaceutical formulation of claim 1, further comprising at least one amino acid selected from the group consisting of histidine or arginine.

3. The pharmaceutical formulation of claim 1 comprising: (i) about 0.2 to 75 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.02 to 0.5% polysorbate 20; and (iii) about 5 to 10% sucrose.

4. The pharmaceutical formulation of claim 3, comprising: (i) about 0.6-60 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.5% polysorbate 20; and (iii) about 8% sucrose.

5. The pharmaceutical formulation of claim 1, further comprising:

a glass container selected from the group consisting of a glass vial, a glass syringe, a plastic vial, and a plastic syringe.

6. The formulation of claim 5, wherein the container is a glass vial comprising a silicon dioxide coated glass.

7. The formulation of claim 6, wherein the glass vial is filled with the formulation leaving headspace filled with an inert gas.

8. The formulation of claim 7, wherein the inert gas is selected from the group consisting of argon and nitrogen.

9. The pharmaceutical formulation of claim 1, further comprising:

a container selected from the group consisting of an autoinjector, and a microinfusor.

10. The pharmaceutical formulation of claim 5, wherein the glass container is the syringe and the syringe is a syringe comprising a fluorocarbon-coated plunger.

11. The pharmaceutical formulation of claim 10, wherein the syringe is a low tungsten syringe.

12. The pharmaceutical formulation of claim 11, wherein the syringe comprises a fluorocarbon-coated plunger.

13. A pharmaceutical formulation comprising:

(i) about 0.1-100 mg/mL of a human antibody that specifically binds to human nerve growth factor (hNGF);

(ii) about 0.05% polysorbate 20;

(iii) about 8% sucrose; and

(iv) about 10 mM acetate,

wherein said antibody comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pairs selected from the group consisting of: (a) SEQ ID NOs:20/22; and (b) SEQ ID NOs 4/12,

wherein 90% or more of the antibody is detected by size-exclusion-high-performance liquid chromatography (SE-HPLC) when stored at 5°C for six months.

14. The pharmaceutical formulation of claim 13, wherein the pH of the formulation ranges from about 4.5 to 5.6.

15. The pharmaceutical formulation of claim 14, wherein the pH of the formulation is 5.0.

16. The pharmaceutical formulation of claim 13, further comprising:

a glass container selected from the group consisting of a glass vial, a glass syringe, a plastic vial, and a plastic syringe.

17. The formulation of claim 16, wherein the container is a glass vial comprising a silicon dioxide coated glass.

18. The formulation of claim 17, wherein the glass vial is filled with the formulation leaving headspace filled with an inert gas.

19. The formulation of claim 18, wherein the inert gas is selected from the group consisting of argon and nitrogen.

20. The pharmaceutical formulation of claim 13, further comprising:
a container selected from the group consisting of an autoinjector, and a microinfusor.

21. The pharmaceutical formulation of claim 16, wherein the glass container is the syringe and the syringe is a syringe comprising a fluorocarbon-coated plunger.

22. The pharmaceutical formulation of claim 21, wherein the syringe is a low tungsten syringe.

23. The pharmaceutical formulation of claim 22, wherein the syringe comprises a fluorocarbon-coated plunger.

24. The pharmaceutical formulation of claim 1 or 13, wherein 95% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.

25. The pharmaceutical formulation of claim 1 or 13, wherein 96% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.

26. The pharmaceutical formulation of claim 1 or 13, wherein 97% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.